Dr. Amir Landi
Amir Landi is a formally trained medical doctor (MD), immunologist (PhD) with mastery in cellular immunology/vaccinology, and professional public health leader (MPH candidate) with specialization in Global Health.
In addition to his clinical experiences, leadership in laboratory medicine and public health systems under WHO guidelines, he has 20 years of comprehensive and diverse experiences in leading and performing basic/translational research in Canadian BSC level BSL2-Enhanced and GLP laboratories with GMP-compatible QC/QA documentation, in the field of immunology, vaccinology, virology, autoimmune liver diseases, biomarker research, medical diagnostics, and myalgic encephalitis, for which he is one of the well-known leading scientists of Canada. He is expert in professional leadership, evidence synthesis, program evaluation/indicator definition & construction, data processing/analysis/validation, and project management in the field of public health.
Dr. Landi is currently working as a senior scientist and principal investigator with the 2020 Nobel Prize Winner in Li Ka Shing Applied Virology Institute at the University of Alberta, which is ranked as the 92nd University of the world in 2022*. Amir has had an instrumental role in developing a hepatitis C vaccine, which will be entering the clinic in 2023-2024, a true example of Bench-to-Bedside research. He has 11 issued and >10 ongoing patents, published 24 papers in peer-reviewed scientific journals, and presented at more than 60 national/international scientific meetings as invited speaker and presenter.
Dr. Landi is serving Gain Medical Group as the Senior Scientific Advisor/Consultant.
